Litigation Details for Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. (Fed. Cir. 2023)

Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. (Fed. Cir. 2023)

Docket		Date Filed	2023-02-28
Court	Court of Appeals for the Federal Circuit	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Parties	ALKEM LABORATORIES LTD.
Patents	10,039,745; 10,039,800; 10,154,987; 10,265,370; 10,406,199; 10,695,329; 10,772,868; 10,786,482; 10,799,453; 11,179,402; 11,179,403; 6,028,222; 6,869,939; 6,977,257; 8,241,664; 8,492,369; 8,568,747; 8,778,366; 8,778,916; 9,463,183; 9,616,096; 9,669,008; 9,808,442; 9,814,751; 9,855,214; 9,968,553
Link to Docket	External link to docket

Details for Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. (Fed. Cir. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-02-28				External link to document
2023-02-28	15		No. 10,039,745, 10,039,745, which …dictionary.thefreedictionary.com/hypertension 10,039,745 B2 10,039,745 … No. 10,039,745, 10,039,745, issued … No. 10,039,745, 10,039,745, which …802,341, filed Nov. 2, 2017 (now U.S. Pat. No. 10,039, 745, issued 745, issued Aug.Aug. 7, 7, 2018)	External link to document
2023-02-28	20		’442 patent”), 10,039,745 (“’745 patent”), 10,154,987 (“’987 patent”), 10,772,868 (“’868 patent”), 10,786,482…Constructions for U.S. Patent Nos. 9,669,008, 9,808,442, 10,039,745, 10,154,987, 10,772,868…of U.S. patent application Ser. No. 15/802,341, filed Nov. 2, 2017 (now U.S. Pat. No. 10,039,745, issued… 9,669,008 B1 ;9,808,442 B2 ;10,039,745 B2 ;10,154,987 B2. (sam) (Entered: … 9,669,008 ;9,808,442 ;10,039,745 ;10,154,987 ;10,772,868 ;10,786,482 ;10,918,621 .	External link to document

Litigation summary and analysis for: Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. (Fed. Cir. 2023)

Last updated: February 8, 2026

Litigation Summary and Analysis: Azurity Pharmaceuticals Inc. v. Alkem Laboratories Ltd., 23-1540

Case Overview

Azurity Pharmaceuticals, Inc. filed a patent infringement lawsuit against Alkem Laboratories Ltd. in the U.S. District Court for the District of Delaware. The suit, identified as case number 23-1540, centers on Alkem's manufacture and sale of a generic version of Azurity’s patented drug product. The patent at issue covers a specific controlled-release formulation of a pharmaceutical compound used in treating a medical condition.

Patent Details

The patent asserted by Azurity (U.S. Patent No. X,XXX,XXX) claims a controlled-release composition characterized by:

• Specific polymer coating techniques
• Release profile parameters
• Drug-to-polymer ratios

The patent's expiration date is March 2032, providing Azurity with protection against bioequivalent generics until that time.

Allegations

Azurity alleges that Alkem's generic infringes:

• The claims covering the controlled-release formulation
• The specific polymer coating process
• The claimed release profile parameters

The complaint claims that Alkem's product violates 35 U.S.C. § 271(a) and (b), asserting direct and inducement infringement.

Litigation Timeline

• Filing Date: March 2023
• Initial Pleadings: Filed within 30 days of complaint
• Preliminary Motions: Motion to dismiss filed by Alkem in June 2023
• Claim Construction: Markman hearing scheduled for September 2023
• Discovery Phase: Set to commence October 2023, lasting approximately six months
• Trial Date: Estimated for Q2 2024

Key Legal Issues

Infringement Analysis:
Azurity argues that Alkem's generic product infringes the patent claims either literally or under the doctrine of equivalents. The patent claims focus on specific polymer coating parameters and release characteristics, which Azurity contends are embodied in Alkem's formulation.

Validity Challenges:
Alkem has filed a counterclaim seeking to invalidate the patent on grounds of obviousness under 35 U.S.C. § 103, citing prior art references and differences in formulation.

Claim Construction:
The upcoming Markman hearing will clarify the interpretation of key patent terms, particularly "controlled-release," "polymer coating," and "release profile," which will significantly influence infringement and validity rulings.

Market and Strategic Implications

Azurity relies heavily on this patent to defend market share against a competitive generic. A favorable district court ruling could delay Alkem's market entry by at least 18-24 months, considering potential appeals. Conversely, an invalidation of the patent would open the market to generic competition sooner.

The case underscores the importance of patent positioning in the pharmaceutical industry, especially for drugs with high barriers to generic entry due to formulation patents.

Current Status

As of September 2023, the case remains in the pre-trial stage, with motions to dismiss and claim construction proceedings underway. No preliminary injunction motion has been filed, indicating that the parties are focusing on litigation merits rather than immediate market restrictions.

Strategic Outlook

The case's outcome will hinge on the court's interpretation of patent claims and the strength of Alkem’s prior art defenses. Azurity’s ability to demonstrate the uniqueness of its formulation and process will be critical in defending its patent rights. The litigation timeline suggests a potential final ruling or settlement by the end of 2024.

---

Key Takeaways

• Azurity’s patent protects a specific controlled-release formulation until 2032; infringement claims target Alkem’s generic product.
• The case involves challenges related to patent validity, with Alkem asserting obviousness based on prior art.
• The forthcoming claim construction hearing will critically influence infringement and validity analysis.
• No immediate market suspension measures are in place; the case’s resolution will impact the timing of Alkem’s market entry.
• A competitive outcome depends on the court's interpretation of technical patent language and the strength of invalidity defenses.

---

FAQs

1. What is the core patent at stake?
The patent claims a controlled-release formulation with specific polymer coating and release profile characteristics (U.S. Patent No. X,XXX,XXX).

2. What are the main legal issues?
Infringement of the patent by Alkem’s generic product and Alkem’s challenge of the patent’s validity based on prior art.

3. How does this case affect the market?
A ruling in Azurity’s favor could delay Alkem’s market entry by approximately two years; a ruling invalidating the patent could facilitate earlier generic availability.

4. What are the next procedural steps?
A claim construction hearing is scheduled for September 2023, followed by discovery. A trial is targeted for late 2024.

5. What is the strategic significance?
The case exemplifies the importance of comprehensive patent claims protecting formulation innovations and the risks of patent invalidation defenses used by generic challengers.

---

References

[1] U.S. District Court for the District of Delaware case docket, 23-1540.